EM1710E "SGLT 2 Inhibitors Improve CardioRenal Outcomes in DM2 – Get Rid of the Sugar" (IM GR-100617)
Purpose and Overview: Review treatment options for DM2, emphasizing the improved CV and Renal outcomes with SGLT2 Inhibitors.
UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.
At the conclusion of this activity, the participant should be able to:
- Appreciate the rising incidence of DM2 and increased CV risks with DM2
- Recall the lack of CV outcome benefits with SU’s, TZD’s, DPP4 inhibitors.
- Appreciate the improved CV and Renal outcomes with SGLT2 Inhibitors, as well as GLP1 agonists
David S. Balis, M.D.
Professor of Internal Medicine
Division of General Internal Medicine
- 1.00 AMA